Treatment for Enteropathic E. coli Without Shiga Toxin

Diagnostic Approach

The Infectious Diseases Society of America recommends evaluating for fever, abdominal pain, bloody stools, and presence of fecal leukocytes, which are common features of enteropathic E. coli infections 3
The Centers for Disease Control and Prevention suggest considering stool testing for patients with diarrheal illness lasting >1 day, especially if accompanied by fever, bloody stools, systemic illness, recent antibiotic use, day-care attendance, hospitalization, or dehydration 3, 4
The American Gastroenterological Association recommends diagnostic testing should include stool culture specifically for enteropathogenic E. coli 5, 6

The American College of Physicians recommends first-line therapy with fluoroquinolones (e.g., ciprofloxacin) or azithromycin depending on local susceptibility patterns for adults 1, 2
The American Academy of Pediatrics recommends first-line therapy with azithromycin or a third-generation cephalosporin depending on local susceptibility patterns for children 1, 2
For immunocompromised patients, the Infectious Diseases Society of America recommends considering empiric antibacterial treatment with more aggressive monitoring 1, 2

The World Health Organization recommends fluid and electrolyte replacement as the cornerstone of management 1, 2
The American Academy of Pediatrics recommends using reduced osmolarity oral rehydration solution (ORS) as first-line therapy for mild to moderate dehydration 1, 2
For severe dehydration, shock, altered mental status, or failure of oral rehydration therapy, the Centers for Disease Control and Prevention recommend administering isotonic intravenous fluids (lactated Ringer's or normal saline) 1, 7

The Infectious Diseases Society of America emphasizes the critical distinction between treatment approaches for non-Shiga toxin E. coli and Shiga toxin-producing E. coli (STEC) 7
The American College of Physicians recommends avoiding antibiotics in STEC infections due to increased risk of hemolytic uremic syndrome (HUS) 1, 7
The Centers for Disease Control and Prevention recommend avoiding antimotility agents as they can potentially worsen outcomes, especially if the strain produces toxins 7
The World Health Organization suggests considering local resistance patterns when selecting empiric therapy 1, 2